Teyi Pharmaceutical Group Co.,Ltd
SZSE:002728.SZ
17.38 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 1,054.931 | 886.571 | 758.16 | 632.695 | 921.122 | 884.976 | 686.944 | 655.857 | 516.54 | 344.748 | 342.721 | 340.827 | 305.131 | 250.808 | 202.139 |
Cost of Revenue
| 496.538 | 451.833 | 356.076 | 327.088 | 374.504 | 363.842 | 355.743 | 342.735 | 282.662 | 192.398 | 193.791 | 198.75 | 183.679 | 163.56 | 151.392 |
Gross Profit
| 558.394 | 434.738 | 402.085 | 305.608 | 546.618 | 521.134 | 331.201 | 313.121 | 233.879 | 152.35 | 148.93 | 142.077 | 121.453 | 87.247 | 50.747 |
Gross Profit Ratio
| 0.529 | 0.49 | 0.53 | 0.483 | 0.593 | 0.589 | 0.482 | 0.477 | 0.453 | 0.442 | 0.435 | 0.417 | 0.398 | 0.348 | 0.251 |
Reseach & Development Expenses
| 39.028 | 38.01 | 37.777 | 36.499 | 44.383 | 46.626 | 46.163 | 50.806 | 26.343 | 17.114 | 16.283 | 15.37 | 13.978 | 0 | 0 |
General & Administrative Expenses
| 13.309 | 9.696 | 12.947 | 13.957 | 18.575 | 19.985 | 13.316 | 14.031 | 20.668 | 7.011 | 5.016 | 4.438 | 4.389 | 17.22 | 14.216 |
Selling & Marketing Expenses
| 174.359 | 117.399 | 118.735 | 98.917 | 205.594 | 200.07 | 103.011 | 89.682 | 74.365 | 35.893 | 28.201 | 24.795 | 18.403 | 14.252 | 6.649 |
SG&A
| 216.194 | 127.095 | 131.682 | 112.875 | 224.168 | 220.055 | 116.327 | 103.714 | 95.033 | 42.904 | 33.217 | 29.232 | 22.792 | 31.472 | 20.865 |
Other Expenses
| 3.456 | 50.609 | 49.545 | 46.013 | 40.637 | -4.76 | 3.659 | 5.542 | 3.52 | -3.889 | -2.767 | 1.139 | 3.905 | 2.35 | 0.817 |
Operating Expenses
| 251.767 | 215.714 | 219.004 | 195.387 | 309.188 | 307.801 | 197.729 | 194.951 | 141.997 | 70.27 | 58.473 | 53.736 | 44.625 | 32.902 | 21.73 |
Operating Income
| 306.627 | 196.548 | 201.428 | 121.741 | 197.576 | 181.915 | 115.954 | 100.438 | 91.768 | 90.301 | 93.268 | 88.282 | 77.014 | 53.528 | 27.177 |
Operating Income Ratio
| 0.291 | 0.222 | 0.266 | 0.192 | 0.214 | 0.206 | 0.169 | 0.153 | 0.178 | 0.262 | 0.272 | 0.259 | 0.252 | 0.213 | 0.134 |
Total Other Income Expenses Net
| -13.633 | -0.223 | -54.329 | -68.463 | -0.717 | -36.177 | -13.859 | -12.775 | 3.37 | 10.946 | 3.01 | 3.075 | 4.19 | 1.532 | -1.023 |
Income Before Tax
| 292.994 | 196.325 | 147.099 | 53.278 | 196.86 | 177.156 | 119.613 | 105.396 | 95.252 | 93.026 | 93.467 | 91.416 | 81.018 | 55.877 | 27.994 |
Income Before Tax Ratio
| 0.278 | 0.221 | 0.194 | 0.084 | 0.214 | 0.2 | 0.174 | 0.161 | 0.184 | 0.27 | 0.273 | 0.268 | 0.266 | 0.223 | 0.138 |
Income Tax Expense
| 39.818 | 18.121 | 20.182 | 9.462 | 25.149 | 21.609 | 13.27 | 10.619 | 14.147 | 12.832 | 12.912 | 12.837 | 11.323 | 7.893 | 3.894 |
Net Income
| 253.176 | 178.204 | 126.917 | 43.816 | 171.71 | 155.546 | 106.343 | 94.777 | 81.105 | 80.194 | 80.555 | 78.578 | 69.695 | 47.985 | 24.1 |
Net Income Ratio
| 0.24 | 0.201 | 0.167 | 0.069 | 0.186 | 0.176 | 0.155 | 0.145 | 0.157 | 0.233 | 0.235 | 0.231 | 0.228 | 0.191 | 0.119 |
EPS
| 0.77 | 0.57 | 0.41 | 0.15 | 0.61 | 0.56 | 0.38 | 0.34 | 0.29 | 0.34 | 0.38 | 0.38 | 0.33 | 0.24 | 0.13 |
EPS Diluted
| 0.77 | 0.57 | 0.41 | 0.15 | 0.6 | 0.56 | 0.38 | 0.34 | 0.29 | 0.34 | 0.38 | 0.38 | 0.33 | 0.24 | 0.13 |
EBITDA
| 366.802 | 279.41 | 252.734 | 172.771 | 288.842 | 263.206 | 173.753 | 156.432 | 114.793 | 90.017 | 100.805 | 100.381 | 87.986 | 60.725 | 35.394 |
EBITDA Ratio
| 0.348 | 0.315 | 0.333 | 0.273 | 0.314 | 0.297 | 0.253 | 0.239 | 0.222 | 0.261 | 0.294 | 0.295 | 0.288 | 0.242 | 0.175 |